Since it’s inception on November 15, 2023, the fund strategically invests in innovative clinical-stage and early product-stage public biotech equities to deliver hope to patients worldwide. Positioned to outperform market benchmarks such as the Dow Jones Industrial Average (INDU) and Nasdaq Biotechnology Index (NBI), and SPDR S&P 500 ETF Trust (SPY) in the long term, we are poised to deliver superior returns for our investors. As of September 19, 2024, Evergrowth returned over 52.41% since inception. Note this is unaudited records.